Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal

September 22, 2009 8:43 AM EDT Send to a Friend
Get Alerts NKTR Hot Sheet
Price: $12.64 --0%

Rating Summary:
    7 Buy, 1 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 5
Trade NKTR Now!
Join SI Premium – FREE
Morgan Joseph reiterates a 'Buy' on Nektar Technology (Nasdaq: NKTR), raises price target from $9 to $12.

Morgan analyst says, "Yesterday, Nektar announced a $1.5 billion worldwide license agreement with AstraZeneca (NYSE: AZN) to develop and market NKTR-118 and NKTR-119. Although we had anticipated a transaction, the size of the deal and the quality of the partner has meaningfully increased our confidence in the potential of NKTR-118, and Nektar's technology. Our key takeaway from this deal is that despite its low development-risk profile, Nektar's technology could add substantial value to shareholders."

To see more analyst ratings on NKTR Click Here.

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

UBS, Morgan Joseph

Add Your Comment